JUNS
NASDAQJupiter Neurosciences Inc.
News · 26 weeks73-44%
2026-03-012026-08-23
Mix4790d
- SEC Filings21(45%)
- Insider18(38%)
- Other6(13%)
- Leadership1(2%)
- Offering1(2%)
Latest news
25 items- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECSEC Form 424B5 filed by Jupiter Neurosciences Inc.424B5 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- PRJupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingNew York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acting as the exclusive placement agent for the Offering. The closing of the Offering is expected to occur on or about August 24, 2026, subject to the satisfaction of customary closing conditions. Th
- PRPharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking PartnerU.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO)PharmAla has exercised its option to cancel the proposed licensing of APA-01 to Restora Neurosciences, and will evaluate in-house and co-development pathwaysCanaccord Genuity LLC has been engaged as exclusive financial advisor and placement agent TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE:MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today
- SECSEC Form 10-Q filed by Jupiter Neurosciences Inc.10-Q - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- INSIDERSEC Form 4 filed by Director Cutler Andrew Jon4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- PRJupiter Neurosciences, Inc. Announces Reverse Stock SplitJupiter’s common stock is expected to begin trading on a post-split adjusted basis on August 7, 2026 JUPITER, FL, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and neurodegenerative disorders, today announced that the board of directors of the Company approved a 1-for-75 reverse stock split (the "Reverse Split") of the Company’s common stock. The Reverse Split was approved by the stockholders at the Company’s annual meeting of the stockholders held on July 22, 2026. The Reverse Split will legally take effect at 4:01 p.m
- SECSEC Form 424B3 filed by Jupiter Neurosciences Inc.424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECSEC Form 424B3 filed by Jupiter Neurosciences Inc.424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- INSIDERSEC Form 3 filed by new insider Cutler Andrew Jon3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- SECSEC Form 424B3 filed by Jupiter Neurosciences Inc.424B3 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- SECJupiter Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- PRJupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 MillionTransaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) today announced that it has entered into a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002. The transaction has a potential value of up to $100 million, including milestone payments, and expands Jupiter from a single-program company into a dual clinical-stage CNS developer. Management believes the transaction strengthens the Company through diversification acr
- PRPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE:MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has entered into a definitive license agreement (the "Agreement") on July 20th, 2026 with Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter"), under which PharmAla has granted Jupiter an exclusive, perpetual, royalty-bearing license to develop, manufacture and commercialize ALA-002, PharmAla’s lead drug candidate, in the United States. PharmAla retains all rights to ALA-002 outside the United
- INSIDERChief Administrative Officer Rosen Alexander Gustaf Erik converted options into 261,161 shares, increasing direct ownership by 73% to 617,411 units (SEC Form 4)4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERDirector Kampf Julie B. converted options into 82,875 shares (SEC Form 4)4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERDirector Weis Holger converted options into 85,800 shares, increasing direct ownership by 796% to 96,581 units (SEC Form 4)4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERDirector Hemmerly Nicholas H. converted options into 95,550 shares (SEC Form 4)4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- INSIDERChief Scientific Officer Hayward Marshall A. converted options into 1,014,195 shares, increasing direct ownership by 51% to 2,995,077 units (SEC Form 4)4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
- SECSEC Form EFFECT filed by Jupiter Neurosciences Inc.EFFECT - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
- PRJupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. PhilipsonFormer White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter Neurosciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced the appointment of Tomas J. Philipson, Ph.D., a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both the Audit Committee and Compensation Committee, bringing unparalleled expertise in health economics, reg
JUNS FAQ
5 questionsWhere does JUNS stock trade?
Jupiter Neurosciences Inc. (JUNS) is listed on NASDAQ.What sector and industry is JUNS in?
Jupiter Neurosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Jupiter Neurosciences Inc. go public?
Jupiter Neurosciences Inc. (JUNS) completed its IPO in 2024.What companies are similar to JUNS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare JUNS side-by-side with any of them on Quantisnow.How can I track JUNS on Quantisnow?
Quantisnow aggregates Jupiter Neurosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JUNS to receive live email and push alerts on every new disclosure.